人PD1基因真核表达载体构建与鉴定
Construction and Identification of Eukaryotic Expression Vector of Human Programmed Death Receptor 1
DOI: 10.12677/BP.2018.83007, PDF,    科研立项经费支持
作者: 穆宇灵, 杨 霄, 康宇佳, 石金磊*:上海科技大学 生命科学与技术学院,上海
关键词: PD1重组质粒EGFPWestern Blot转染PD1 Recombinant Plasmid EGFP; Western Blot Transfection
摘要: 目的:构建含EGFP标签的人程序性死亡受体(hPD-1)的真核表达载体,为后续基因转移实验奠定基础。方法:PCR扩增hPD-1基因编码框,将PD-1和pEGFP-N1质粒双酶切后进行连接转化,构建重组载体pEGFP-N1-PD-1,酶切重组质粒并测序鉴定,将构建好的重组质粒转染HEK293T细胞,并提取蛋白进行Western blot检测。结果:重组真核表达载体pEGFP-N1-PD-1经限制性内切酶分析,双酶切之后的条带与理论值相符,测序结果未见碱基变异,提取转染后细胞的总蛋白进行Western blot可以检测到目标条带。结论:成功构建了pEGFP-N1-PD-1真核表达载体,并且能够在293T细胞中正常表达,为后续研究PD-1基因的功能奠定基础。
Abstract: Objective: To construct a eukaryotic expression vector containing human EGFP-tagged human programmed death receptor (hPD-1), which lays a foundation for subsequent gene transfer expe-riments. Methods: The hPD-1 gene coding frame was amplified by PCR. The PD-1 and pEGFP-N1 plasmids were digested and ligated, and the recombinant vector pEGFP-N1-PD-1 was constructed. The recombinant plasmid was digested and sequenced for identifying. The recombinant plasmid was transfected into HEK293T cells, and the protein was extracted for Western blot analysis. Re-sults: The recombinant eukaryotic expression vector pEGFP-N1-PD-1 was analyzed by restriction endonuclease. The bands after double digestion were consistent with the theoretical values. No nucleotide variation was observed in the sequencing results. The total protein of the transfected cells was extracted. Western blot can detect the target band. Conclusion: The eukaryotic expression vector pEGFP-N1-PD-1 was successfully constructed and expressed in 293T cells, which laid a foundation for the subsequent study of the function of PD-1 gene.
文章引用:穆宇灵, 杨霄, 康宇佳, 石金磊. 人PD1基因真核表达载体构建与鉴定[J]. 生物过程, 2018, 8(3): 55-60. https://doi.org/10.12677/BP.2018.83007

参考文献

[1] Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death. EMBO Journal, 11, 3887-3895.
[2] Nishimura, H., Nose, M., Hiai, H., Minato, N. and Honjo, T. (1999) Development of Lupus-Like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity, 11, 141-151. [Google Scholar] [CrossRef
[3] Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., et al. (2001) Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science, 291, 319-322. [Google Scholar] [CrossRef] [PubMed]
[4] Dong, H., Zhu, G., Tamada, K. and Chen, L. (1999) B7-H1, a Third Member of the B7 Family, Costimulates T-Cell Proliferation and Interleukin-10 Secretion. Nature Medicine, 5, 1365-1369. [Google Scholar] [CrossRef] [PubMed]
[5] Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., et al. (2000) Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 192, 1027-1034. [Google Scholar] [CrossRef] [PubMed]
[6] Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., et al. (2001) PD-L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation. Nature Immunology, 2, 261-268. [Google Scholar] [CrossRef] [PubMed]
[7] Tseng, S.Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J.E., et al. (2001) B7-DC, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells. Journal of Experimental Medicine, 193, 839-846. [Google Scholar] [CrossRef] [PubMed]
[8] Keir, M.E., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
[9] Böger, C., Behrens, H.M., Mathiak, M., et al. (2016) PD-L1 Is an Independent Prognostic Predictor in Gastric Cancer of Western Patients. Oncotarget, 7, 24269-24283. [Google Scholar] [CrossRef] [PubMed]
[10] Iraolagoitia, X.L., Spallanzani, R.G., Torres, N.I., et al. (2016) NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. Journal of Immunology, 197, 953-961. [Google Scholar] [CrossRef] [PubMed]
[11] Leng, C., Li, Y., Qin, J., et al. (2016) Relationship between Expression of PDL1 and PD-L2 on Esophageal Squamous Cell Carcinoma and the Antitumor Effects of CD8+ T Cells. Oncology Report, 35, 699-708. [Google Scholar] [CrossRef] [PubMed]
[12] Hughes, P.E., Caenepeel, S., Wu, L.C., et al. (2016) Targeted Therapyand Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 37, 462-476. [Google Scholar] [CrossRef] [PubMed]
[13] 谢丽叶, 付杰军, 卢奕, 张健. PD1/PD-L1激活促进癌症发生、发展和转移的研究进展[J]. 肿瘤防治研究, 2017, 44(6): 423-427.
[14] 赵宇飞, 陈晓, 李薇. PD1/PD-L1抑制剂治疗肿瘤[J]. 中国肿瘤生物治疗杂志, 2017, 24(8): 904-911.
[15] Koh, Y.W., Jeon, Y.K., Yoon, D.H., et al. (2016) Programmed Death 1expression in the Peritumoral Microenvironment Is Associated with a Poorer Prognosis in Classical Hodgkin Lymphoma. Tumor Biology, 37, 7507-7514. [Google Scholar] [CrossRef] [PubMed]